

10/573232  
JAP20 Rec'd PCT/PTO 23 MAR 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Philippe G. Nantermet	
Serial No.:	To Be Assigned	Case No.: 21546YP
US Nat'l Filing Date:	March 23, 2006	
Int'l Appl'n No.	PCT/US2004/032009	
Int'l Filing Date:	September 29, 2004	
For:	BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE	

MAIL STOP PCT  
Commissioner for Patents  
P.O. BOX 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT March 23, 2006  
EXPRESS MAIL NO. EL 989585313 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,  
Alexandria, Virginia 22313-1450

MAILED BY Kathy Kluttsall  
DATE 3-23-06

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./

10/573232

Int'l Appl'n No.: PCT/US2004/032009  
Case No.: 21546YP  
Page 2 of 2  
IAP20PACD PCT/PTO 23 MAR 2006

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

References A and B on the accompanying PTO 1440 form were cited in the International Search Report for this application. A copy of the International Search Report and Written Opinion are enclosed with this Information Disclosure Statement.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By   
John C. Todaro, Reg. No. 36,036  
Attorney for Applicant

MERCK & CO., Inc.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-0125

Date: March 23, 2006

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.W./

**Substitute for form 1449A/PTO**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

*(use as many sheets as necessary)*

Sheet

1

of

1

**COMPLETE IF KNOWN**

**Application Number**

### To Be Assigned

— 1 —

**Filing Date** 6/26/2013

March 23, 2006

2021 RELEASE UNDER E.O. 14176

## **First Named**

Philippe G. Nain

6 AUGUST

T-B-A-i-1

## Group A/H Unit

## To Be Assigned

---

## **U.S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)	
D		WO 89/04833		PCT The Upjohn Company	06/01/1989
E		WO 01/00665		PCT Oklahoma Medical Research Foundation	
				& Board of Trustees of the Univ. of Illinois	01/04/2001
F		WO 2003/072535		PCT Elan Pharmaceuticals and Pharmacia	
				& Upjohn Company	09/04/2003
G		WO 02/02512		PCT Elan Pharmaceuticals and Pharmacia	
				& Upjohn Company	01/10/2002

**Examiner  
Signature**

/Paul Ward/ (12/13/2008)

**Date Considered**

**\*Examiner: Initial all references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and do not consider. Include copy of this form with next communication to applicant.**

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005